Literature DB >> 211234

Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).

L B Allen, K H Boswell, T A Khwaja, R B Meyer, R W Sidwell, J T Witkowski, L F Christensen, R K Robins.   

Abstract

1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide 5'-phosphate (2) was prepared and converted into the following derivatives: the 5'-phosphoramidate 3, the 5'-diphosphate 4, the 5'-triphosphate 5, and the cyclic 3',5'-phosphate 6. The cyclic 2',3'-phosphate 7 was prepared from the parent nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (1), and was opened to the 2'(3')-phosphate 8. These compounds were found to exhibit significant antiviral activity against several viruses in cell culture. Ribavirin 5'-phosphate (2) was shown to be effective when tested against lethal infections in mice caused by influenza A2, influenza B, and murine hepatitis viruses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 211234     DOI: 10.1021/jm00206a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.

Authors:  Hyojin Ko; Ingrid Fricks; Andrei A Ivanov; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

2.  Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction.

Authors:  R Fernandez-Larsson; K O'Connell; E Koumans; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 3.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

4.  A synthetic study on cyclic phosphate derivatives of seconucleosides as potential antiviral agents (I). Synthesis of 3',5'-cyclic phosphates of 2'-substituted secouridines and secoribavirins.

Authors:  K A Hong; J W Yang; S J Chun; E Y Ha; J H Kim; M W Chun; W K Chung
Journal:  Arch Pharm Res       Date:  1991-03       Impact factor: 4.946

5.  Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription.

Authors:  P Toltzis; K O'Connell; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 6.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

7.  Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity.

Authors:  Gary A Levy; Gord Adamson; M James Phillips; Louise A Scrocchi; Laisum Fung; Pieter Biessels; Nancy F Ng; Anand Ghanekar; Andrea Rowe; Max Xuezhong Ma; Adam Levy; Cheryl Koscik; William He; Reginald Gorczynski; Steve Brookes; Caroline Woods; Ian D McGilvray; David Bell
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

Review 8.  T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.

Authors:  Yousuke Furuta; Kazumi Takahashi; Kimiyasu Shiraki; Kenichi Sakamoto; Donald F Smee; Dale L Barnard; Brian B Gowen; Justin G Julander; John D Morrey
Journal:  Antiviral Res       Date:  2009-03-06       Impact factor: 5.970

Review 9.  Antiviral therapeutic approaches for human rhinovirus infections.

Authors:  Victor Casanova; Filipa H Sousa; Craig Stevens; Peter G Barlow
Journal:  Future Virol       Date:  2018-06-12       Impact factor: 1.831

10.  The synthesis, antiviral, cytostatic and cytotoxic evaluation of a new series of acyclonucleotide analogues with a 1,2,3-triazole linker.

Authors:  Iwona E Głowacka; Jan Balzarini; Andrzej E Wróblewski
Journal:  Eur J Med Chem       Date:  2013-10-30       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.